Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|October 28, 2024

Exploring Emerging Data in NMIBC

Author(s)Félix Guerrero-Ramos, MD, PhD, FEBU , Srikala Sridhar, MD , Jens Bedke, MD

Key Takeaways

BladderGATE trial explores frontline use of PD1+BCG, showing promise in bladder cancer treatment advancements.
Enfortamab vedotin and pembrolizumab combination is under investigation, potentially enhancing therapeutic efficacy.
Clinical complete response is a key endpoint, offering insights into treatment success and patient outcomes.
Circulating tumor DNA is emerging as a non-invasive biomarker, aiding in monitoring treatment response and disease progression.

SHOW MORE

Panelists discuss existing and upcoming data in non–muscle-invasive (NMIBC) bladder cancer treatment, including insights from the BladderGATE trial on frontline use of PD-1 inhibitors combined with BCG and the enfortamab vedotin plus pembrolizumab combination while also addressing the significance of clinical complete response as an end point and the potential role of circulating tumor DNA in future evaluations.

Episodes in this series

EP. 1 Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP. 1 Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP. 2 NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP. 2 NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP. 3 Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP. 3 Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP. 4 Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP. 4 Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP. 5 Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP. 5 Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP. 6 Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP. 6 Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP. 7 Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP. 7 Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP. 8 Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP. 8 Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP. 9 Exploring Emerging Data in NMIBC

EP. 9 Exploring Emerging Data in NMIBC

EP. 10 Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

EP. 10 Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Video content above is prompted by the following:

What other data exists? What upcoming data are you excited about? * (bladdergate, First Results of the Phase Ib-II BladderGATE exploring frontline use of PD1+BCG etc.)
Enfortamab vedotin plus pembrolizumab combination
Please discuss clinical complete response as an end point for these trials. What about circulating tumor DNA?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Surabhi Amar, MD, MHA, MBBS; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

FDA approves first-line Zenflow system for the treatment of BPH

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC

FDA approves gepotidacin for uncomplicated urogenital gonorrhea

© 2025 MJH Life Sciences^®

All rights reserved.